Story perspectives

Johnson & Johnson's Oral Psoriasis Pill Gets FDA Approval

3/19/2026

Summary

Story summary

Johnson & Johnson announced FDA approval for Icotyde, the first oral IL-23 receptor blocker for moderate-to-severe plaque psoriasis.
The once-daily pill is approved for patients 12 and older eligible for systemic therapy.
Icotyde offers a convenient alternative to Tremfya and Skyrizi, which are injectable.
Clinical trials show 70% achieved clear or almost clear skin at week 16, and Johnson & Johnson is exploring use for psoriatic arthritis and Crohn's disease.

1 of 1

Story summary

Johnson & Johnson announced FDA approval for Icotyde, the first oral IL-23 receptor blocker for moderate-to-severe plaque psoriasis.
The once-daily pill is approved for patients 12 and older eligible for systemic therapy.
Icotyde offers a convenient alternative to Tremfya and Skyrizi, which are injectable.
Clinical trials show 70% achieved clear or almost clear skin at week 16, and Johnson & Johnson is exploring use for psoriatic arthritis and Crohn's disease.